220 related articles for article (PubMed ID: 15565326)
1. Description of paclitaxel resistance-associated genes in ovarian and breast cancer cell lines.
Duan Z; Lamendola DE; Duan Y; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2005 Mar; 55(3):277-85. PubMed ID: 15565326
[TBL] [Abstract][Full Text] [Related]
2. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line.
Lamendola DE; Duan Z; Yusuf RZ; Seiden MV
Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840
[TBL] [Abstract][Full Text] [Related]
3. Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype.
Duan Z; Feller AJ; Penson RT; Chabner BA; Seiden MV
Clin Cancer Res; 1999 Nov; 5(11):3445-53. PubMed ID: 10589757
[TBL] [Abstract][Full Text] [Related]
4. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
5. GBP1 overexpression is associated with a paclitaxel resistance phenotype.
Duan Z; Foster R; Brakora KA; Yusuf RZ; Seiden MV
Cancer Chemother Pharmacol; 2006 Jan; 57(1):25-33. PubMed ID: 16028104
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.
Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y
Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma.
Kumar A; Soprano DR; Parekh HK
Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393
[TBL] [Abstract][Full Text] [Related]
8. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
[TBL] [Abstract][Full Text] [Related]
9. The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines.
Takeda M; Mizokami A; Mamiya K; Li YQ; Zhang J; Keller ET; Namiki M
Prostate; 2007 Jun; 67(9):955-67. PubMed ID: 17440963
[TBL] [Abstract][Full Text] [Related]
10. A microarray based expression profiling of paclitaxel and vincristine resistant MCF-7 cells.
Kars MD; Işeri OD; Gündüz U
Eur J Pharmacol; 2011 Apr; 657(1-3):4-9. PubMed ID: 21320484
[TBL] [Abstract][Full Text] [Related]
11. RAIDD expression is impaired in multidrug resistant osteosarcoma cell lines.
Yang C; Hornicek FJ; Wood KB; Schwab JH; Mankin H; Duan Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):607-14. PubMed ID: 19125251
[TBL] [Abstract][Full Text] [Related]
12. [The selection of taxol resistance associated genes in ovarian cancer cell line by mRNA DD].
Cheng G; Tian F; Li Y
Zhonghua Yi Xue Za Zhi; 2000 Jul; 80(7):541-3. PubMed ID: 11798816
[TBL] [Abstract][Full Text] [Related]
13. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
14. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line.
Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H
Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869
[TBL] [Abstract][Full Text] [Related]
15. Expression microarray analysis reveals genes associated with in vitro resistance to cisplatin in a cell line model.
Watson MB; Lind MJ; Smith L; Drew PJ; Cawkwell L
Acta Oncol; 2007; 46(5):651-8. PubMed ID: 17562441
[TBL] [Abstract][Full Text] [Related]
16. Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells.
Okamoto A; Nikaido T; Ochiai K; Takakura S; Saito M; Aoki Y; Ishii N; Yanaihara N; Yamada K; Takikawa O; Kawaguchi R; Isonishi S; Tanaka T; Urashima M
Clin Cancer Res; 2005 Aug; 11(16):6030-9. PubMed ID: 16115948
[TBL] [Abstract][Full Text] [Related]
17. Role of microRNAs in drug-resistant ovarian cancer cells.
Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C
Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650
[TBL] [Abstract][Full Text] [Related]
18. Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells.
Chang H; Jeung HC; Jung JJ; Kim TS; Rha SY; Chung HC
Breast Cancer Res Treat; 2011 Jan; 125(1):55-63. PubMed ID: 20224928
[TBL] [Abstract][Full Text] [Related]
19. The antitumor activities of curcumin and of its isoxazole analogue are not affected by multiple gene expression changes in an MDR model of the MCF-7 breast cancer cell line: analysis of the possible molecular basis.
Poma P; Notarbartolo M; Labbozzetta M; Maurici A; Carina V; Alaimo A; Rizzi M; Simoni D; D'Alessandro N
Int J Mol Med; 2007 Sep; 20(3):329-35. PubMed ID: 17671737
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of paclitaxel (taxol) analogues on MDR-positive human cancer cells.
Distefano M; Scambia G; Ferlini C; Gallo D; De Vincenzo R; Filippini P; Riva A; Bombardelli E; Mancuso S
Anticancer Drug Des; 1998 Jul; 13(5):489-99. PubMed ID: 9702212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]